Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ȩ > ±Û·Î¹ú ÆÄÆ®³Ê > C > Cutting Edge Information
Áö¿ª
Ä«Å×°í¸®·Î ã±â
ÆÄ¸Ó½´Æ¼ÄÃ

Cutting Edge Information

Cutting Edge Information (CEI) ´Â 2002³â ¼³¸³µÇ¾î Á¦¾à, ¹ÙÀÌ¿ÀÅ×Å©, ÀÇ·á±â±â, ÇコÄÉ¾î ºÐ¾ß¸¦ Àü¹®ÀûÀ¸·Î Á¶»çÇÏ´Â ¸®¼­Ä¡»ç ÀÔ´Ï´Ù. CEI°¡ ¹ßÇàÇÏ´Â ¾à°¡ Àü·«, ÀǾàǰ ¸¶ÄÉÆÃ, ÀÓ»ó °³¹ß µîÀÇ °ü·Ã ½ÃÀåÁ¶»çº¸°í¼­´Â ¼¼°èÀÇ »ý¸í°øÇÐ ¾÷°è °ü°èÀڵ鿡°Ô À¯¿ëÇÑ Âü°í ÀÚ·á·Î ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù.

»ó¼¼ ºÐ·ù
Á¦¸ñ °Ë»ö
1 - 25 ¸®ºä (Àüü£º 57 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Launching Pharmaceutical Brands - Formulas for Commercialization Success
»ùÇÃ
»óǰÄÚµå :239231
¹Ì±¹, À¯·´, ±âŸ ÁÖ¿ä ½ÃÀåÀÇ ½ÇÁ¦ 15°³ ºê·£µå¸¦ º¥Ä¡¸¶Ä»ÇßÀ¸¸ç, °¢ ºê·£µåÀÇ ´Ü°è 3AºÎÅÍ ½ÂÀαîÁö, ½ÂÀκÎÅÍ ¹ß¸ÅÀϱîÁö, ¹ß¸ÅÀϺÎÅÍ 6°³¿ù±îÁöÀÇ ±â°£º° ÅõÀÚ »óȲ, °³º° ÁöÃâ Ç׸ñ¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2012³â 04¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 302 Pages
Regulatory Affairs - Safeguarding Submission success and Product Development Strategy
»ùÇÃ
»óǰÄÚµå :239228
ÀÇ·á¿¡ °üÇÑ ¹ý±ÔÁ¦ °ü·Ã ¾÷¹«¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ¹ý±ÔÁ¦ °ü·Ã ¾÷¹«¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ Àοø ¹èÄ¡ ¹× ¿¹»ê, º¥Ä¡¸¶Å·, ¾ö°ÝÇÑ ±ÔÁ¦ ȯ°æÀ» ±Øº¹Çϱâ À§ÇÑ Àü·«»ó Á¦¾È, º£½ºÆ® ÇÁ·¢Æ¼½º µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2012³â 04¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 111 Pages
Pharmaceutical Patient Adherence and Compliance
»ùÇÃ
»óǰÄÚµå :235919
»ý¸í°úÇÐ ±â¾÷ÀÇ È¯ÀÚ ¼øÀÀµµ ¹× Áؼö(Patient Adherence and Compliance, Ä¡·á ¹× º¹¾à Áö½Ã Áؼö) Çâ»óÀ» À§ÇÑ ´ëó¸¦ Áö¿ªº°·Î Á¶»ç ºÐ¼®Çϰí, ´ã´ç ºÎ¼­ À¯¹«, ´ã´ç ºÎ¼­ ±¸¼º, ¿¹»ê°ú ¿¹»ê ¹èºÐ, ÀÌ¿ë Åø ¹× Ç÷§Æû, À¯È¿ÇÑ ½ÇÇà °æ·Î ºÐ¼®, ÇÁ·Î±×·¥ ½ÇÇàÀÇ °úÁ¦, ÁÖ¿ä 10»çÀÇ ÇÁ·Î±×·¥ °³¿ä µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2012³â 04¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 153 Pages
US Managed Markets: Driving Commercial Success through Outcomes-Based Reimbursement
»ùÇÃ
»óǰÄÚµå :233268
¹Ì±¹ÀÇ ÀǾà, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö, ÀÇ·á±â±â °ü·Ã »ç¾÷ÀÚÀÇ ¸Å´ÏÁöµå ¸¶ÄÏ(Managed Markets) ºÎ¹®¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ¸Å´ÏÁöµå ¸¶ÄÏ ºÎ¹® ±¸Á¶, ÀÎÀç, ¿¹»ê ÇöȲ, ÀÇ·áºñ ÁöºÒÀÚ¿ÍÀÇ °ü°è ±¸Ãà, À¯Áö, °³¼±À» À§ÇÑ °¢Á¾ Àü·«, ÀÇ·áºñ ÁöºÒÀÚ¿¡ ´ëÇÑ ¾îÇÁ·ÎÄ¡ ÇÁ·Î¼¼½º, ¸Å´ÏÁöµå ¸¶ÄÏ ºÎ¹®ÀÌ Á÷¸éÇϰí ÀÖ´Â °¢Á¾ °úÁ¦ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2012³â 03¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 115 Pages
Companion Diagnostics and Biomarker Development
»ùÇÃ
»óǰÄÚµå :231275
¼¼°è ÁÖ¿ä »ç¾÷ÀÚÀÇ µ¿¹ÝÁø´Ü(Companion Diagnostics) ÀǾàǰ°ú ¹ÙÀÌ¿À¸¶Ä¿(Biomarker) °³¹ß µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, °¢»çÀÇ °³¹ß Àü·«, ½ºÄÉÁÙ, ÀÚ¿ø, ±â¾÷°£ Á¦ÈÞ µ¿Çâ, °Ë»ç ±¸ºÐº° ±âÈ£, Áúȯ ±¸ºÐº° °³¹ß µ¿Çâ µîÀ» ÅëÇÑ ºñ±³ ºÐ¼® ¹× º£½ºÆ® ÇÁ·¢Æ¼½º¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2012³â 02¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 113 Pages
Strategic Medical Publications Management
»ùÇÃ
»óǰÄÚµå :231274
ÀǾàǰ, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö, ÀÇ·á±â±â ±â¾÷ÀÇ ÀÇÇÐ ³í¹® °ü¸®(Medical Publications Management) ÇöȲ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ÀÇÇÐ ³í¹® °ü¸® º¥Ä¡¸¶Å· ºÐ¼®°ú º£½ºÆ® ÇÁ·¢Æ¼½º¸¦ ¾ò±â À§ÇØ, °ü·Ã ºÎ¹® ±¸Á¶, ÀÎÀç, ¾Æ¿ô¼Ò½Ì µ¿Çâ, ¿¹»ê, ³í¹® ¹ßÇ¥¼ö ÃßÁ¤, ³í¹® ¹ßÇ¥¸¦ À§ÇÑ Àü·«°ú Ȱµ¿ µî °¢Á¾ µ¥ÀÌÅ͸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 160 Pages
Pharmaceutical Portfolio Management
»ùÇÃ
»óǰÄÚµå :225407
ÀǾàǰ ±â¾÷°ú ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷À» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Á¶»ç °á°ú¸¦ ¹ÙÅÁÀ¸·Î Æ÷Æ®Æú¸®¿À ¹× ¼ö¸íÁֱ⠰ü¸®¿¡ ´ëÇÑ º¥Ä¡¸¶Å· ºÐ¼®°ú º£½ºÆ® ÇÁ·¢Æ¼½º¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 97 Pages
Pharmaceutical Digital Marketing and Social Media
»ùÇÃ
»óǰÄÚµå :223943
»ý¸í°úÇÐ ±â¾÷ÀÇ µðÁöÅÐ ¸¶ÄÉÆÃ(Digital Marketing) ¹× ¼Ò¼È ¹Ìµð¾î(Social Media) ÀÌ¿ëÀ» Á¶»ç ºÐ¼®Çϰí, »õ·Î¿î ¸¶ÄÉÆÃ ¹Ìµð¾î ±¸¼º, ¼Ò¼È ¹Ìµð¾î µµÀÔ µ¿Çâ, eMarketing ºÎ¹®ÀÇ ±¸¼º, ÀÎÀç, ¿¹»ê, ´ë¸®Á¡ ÀÌ¿ë µî¿¡ °üÇÑ ¾÷°è µ¿Çâ°ú Á¦¾È µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 187 Pages
Health Outcomes Liaisons: Managing a Field-Based Team that Speaks the Payer's Language
»ùÇÃ
»óǰÄÚµå :219123
ÀÇ·áºñ »ó½Â°ú °æÀï ½ÉÈ­·Î »ý¸í°úÇÐ ±â¾÷Àº ºê·£µå ÀǾàǰ°ú Á¦³×¸¯ ÀǾàǰÀ» ºÒ¹®ÇÏ°í °øÁ¤ÇÑ ºñ¿ë°ú Á¦Ç° °¡Ä¡ Áõ¸í¿¡ ²÷ÀÓ¾øÀÌ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. º¸ÇèÀÚ¿Í Ä¿¹Â´ÏÄÉÀ̼ÇÀ» ÃëÇÏ¿© ÃÖ¼±ÀÇ »óȯÀ» È®º¸Çϱâ À§Çؼ­, ±â¾÷Àº °¢°¢ HOL(Health Outcomes Liaisons)À» ¹èÄ¡Çϰí ÀÖ½À´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 128 Pages
Succession Planning: Preparing Tomorrow's Leaders
»ùÇÃ
»óǰÄÚµå :219122
¼¼°è ´ë±â¾÷ 25»çÀÇ »ç·Ê ¿¬±¸¸¦ ±âÃÊ·Î, °è½Â °èȹ(Succession Planning)ÀÇ º£½ºÆ® ÇÁ·¢Æ¼½º¸¦ Á¤¸®ÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 995
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 153 Pages
»ùÇÃ
»óǰÄÚµå :214214
ÁÖ¿ä ±â¾÷ÀÇ ¿¬±¸ÀÚÁÖµµ Àӻ󿬱¸(IIT : Investigator Initiated Trial) °ü¸®¸¦ ºñ±³ºÐ¼®ÇßÀ¸¸ç, È¿°úÀûÀÎ ITT °ü¸® Àü·« ¹× º£½ºÆ® ÇÁ·¢Æ¼½º¸¦ ±¸ÃàÇϱâ À§ÇØ ITT¸¦ À§ÇÑ Á¶Á÷ ±¸¼º, ITT ÇÁ·Î¼¼½ºÀÇ °¢ ´Ü°è¿Í ¼Ò¿äÀϼö, IIT¿¡ ´ëÇÑ ÁöÃâ¾×°ú ¿¹»ê, °³¼± ¿ä±¸ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 111 Pages
Phase IV Clinical Trials: Best Practices in Post-Marketing Study Management
»ùÇÃ
»óǰÄÚµå :214209
Á¦4»ó ÀÓ»ó½ÃÇè ½Ç½Ã¸¦ À§ÇÑ °ü¸® üÁ¦, ½ºÄÉÁÙ, Ȱµ¿ ³»¿ë, ¿¹»ê°ú ¾Æ¿ô¼Ò½Ì µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 197 Pages
Market Access Management: Building Teams That Deliver Value to Payers
»ùÇÃ
»óǰÄÚµå :214213
ÀÇ·áÀÇ ½ÃÀå Á¢±Ù Ȱµ¿ °³¿ä, Á¢±Ù Àü·«°ú °úÁ¦, Á¢±ÙÆÀ Æí¼º, °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 184 Pages
Pharmaceutical Business Development and Licensing: Strengthening Pipelines and Managing Relationships
»ùÇÃ
»óǰÄÚµå :203460
ÀǾàǰ ¾÷°èÀÇ ºñÁö´Ï½º °³¹ß ¹× ¶óÀ̼¾½Ì °è¾à ü°áÀ» À§ÇÑ ÆÀ °á¼º, ÀÚ¿ø, °è¾à °úÁ¤¿¡¼­ÀÇ Àü·« ¼º°øÀ» À§ÇÑ Á¦¾ð µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 121 Pages
KOL Fair-Market Value and Aggregate Spend: Documentation, Tracking and the Sunshine Act
»ùÇÃ
»óǰÄÚµå :203459
KOL(Key Opinion Leader)ÀÇ °øÁ¤½ÃÀå °¡°Ý°ú Àüü ºñ¿ëÀÇ ÀûÀýÇÑ »êÃâÀ» °ËÅäÇϰí, KOLÀÇ º¸¼ö¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â µ¿Çâ, °øÁ¤ ½ÃÀå °¡°Ý(FMV:Fair Market Value)ÀÇ º¥Ä¡¸¶Å·, ¹ý¿¡ ÁذÅÇÑ ÁÖ¿ä ±â¾÷º° KOL º¸¼ö Àü·«, °¡Àå ÀûÀýÇÑ ¹®¼­È­ ½ÇÇà¿¡ °üÇÑ ºÐ¼® µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 314 Pages
Pharmaceutical Brand Lift: Marketing ROI and Budget Allocation
»ùÇÃ
»óǰÄÚµå :192243
ÁÖ¿ä ¸¶ÄÉÆÃ È°µ¿ÀÇ ÅõÀÚȸ¼öÀ²(ROI)°ú ¹®Á¦ÇذáÀ» À§ÇÑ »õ·Î¿î Àü·«, 15°¡Áö ºê·£µå ¾àÁ¦ °³¿ä¸¦ °ËÁõÇϰí, ±âŸ ¿¹»ê¹èºÐ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 05¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 70 Pages
Pharmaceutical Pricing Strategy: Maximize Revenue in an Evolving Economic Climate
»ùÇÃ
»óǰÄÚµå :192242
»ý¸í°úÇÐ ±â¾÷ÀÇ ¾à°¡ ¼³Á¤ µ¿Çâ°ú º¥Ä¡¸¶Å·, ¾à°¡ ¼³Á¤À» À§ÇÑ ÆÀ Æí¼º°ú Ȱµ¿ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 05¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 153 Pages
Clinical Operations: Benchmarking Per-Patient Trial Costs, Staffing and Adaptive Design
»ùÇÃ
»óǰÄÚµå :189452
ÀÓ»ó½ÃÇè ºñ¿ë°ú ¾Æ¿ô¼Ò½Ì µ¿Çâ, ÀÓ»ó½ÃÇè ´Ü°èÀÇ Àοø ¹èÄ¡, ½ÇÀû ÃøÁ¤ ¹æ¹ý, ÀûÀÀÇü ÀÓ»ó½ÃÇè µðÀÚÀÎÀÇ ½Ã°£°ú ºñ¿ë¿¡ °üÇÑ º¥Ä¡¸¶Å·, Áö¼ÓÀûÀÎ ÇÁ·Î¼¼½º °³¼± µ¿Çâ¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 04¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 174 Pages
Specialty and Hospital Sales Force Management
»ùÇÃ
»óǰÄÚµå :189451
Á¦¾àȸ»ç ¿µ¾÷ ºÎ¹®ÀÇ ¿µ¾÷·Â °³¼±À» À§ÇÑ ÅõÀÚ¿Í Àοø ¹èÄ¡, ±³À° ÈÆ·Ã, e-µðÅ×ÀϸµÀÇ È°¿ë µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 04¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 152 Pages
Determining European KOL Compensation: Fair-Market Value Benchmarks
»ùÇÃ
»óǰÄÚµå :174941
À¯·´¿¡¼­ ´Ù¾çÇÑ ±Ô¸ð¿Í ¾÷¹« ¹× ÁöºÒ ÇüŸ¦ °¡Áø ±â¾÷ÀÇ Thought Leader¿¡ ´ëÇÑ º¸»ó ÁöºÒ µ¿ÇâÀ» ºÐ¼®Çϰí, À¯·´ÀÇ ºñ±³, ±â¾÷ ±Ô¸ð, Çüź° ºñ±³ º¥Ä¡¸¶Å©(Benchmarks) µîÀÇ °á°ú¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 03¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 181 Pages
Emerging Markets Clinical Development Series: Brazil, Russia, India and China (BRIC)
»ùÇÃ
»óǰÄÚµå :143474
ºê¶óÁú, ·¯½Ã¾Æ, Àεµ, Áß±¹ (BRIC) ÀÇ ÀÓ»ó°³¹ß ½ÃÀåÀ» ºÐ¼®Çϰí, ±¹°¡º° ÀÓ»ó°³¹ß Àü·«°ú µ¿Çâ, ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2010³â 11¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 275 Pages
Emerging Markets Clinical Development Series: Asia
»ùÇÃ
»óǰÄÚµå :143473
¾Æ½Ã¾ÆÀÇ ÀÓ»ó°³¹ß ½ÃÀåÀ» ºÐ¼®Çϰí, Áß±¹°ú Àεµ¸¦ Áß½ÉÀ¸·Î ±¹°¡º° ÀÓ»ó°³¹ß Àü·«°ú µ¿Çâ, ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2010³â 11¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 193 Pages
Emerging Markets Clinical Development Series: Central and Eastern Europe
»ùÇÃ
»óǰÄÚµå :143472
Áß¾ÓÀ¯·´ ¹× µ¿À¯·´ÀÇ ÀÓ»ó°³¹ß ½ÃÀåÀ» ºÐ¼®Çϰí, ·¯½Ã¾Æ¿Í Æú¶õµå¸¦ Áß½ÉÀ¸·Î ±¹°¡º° µ¿Çâ°ú ÇÁ·ÎÆÄÀÏ, ¸ð¹ü»ç·Ê µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2010³â 11¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 187 Pages
Emerging Markets Clinical Development Series: Africa
»ùÇÃ
»óǰÄÚµå :143471
¾ÆÇÁ¸®Ä«ÀÇ ÀÓ»ó°³¹ß ½ÃÀåÀ» ºÐ¼®Çϰí, ³²¾ÆÇÁ¸®Ä« °øÈ­±¹À» Áß½ÉÀ¸·Î ±¹°¡º° ÀÓ»ó°³¹ß Àü·«°ú µ¿Çâ, ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2010³â 11¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 117 Pages
Medical Device Competitive Intelligence
»ùÇÃ
»óǰÄÚµå :137073
ÀÇ·á±â±â Á¦Á¶¾÷ü¸¦ ´ë»óÀ¸·Î ÇÑ Á¶»ç °á°ú¸¦ Åä´ë·Î, ÀÇ·á±â±â ¾÷°èÀÇ °æÀïÁ¤º¸(CI:Competitive Intelligence) ÆÀ ±¸¼º°ú ¿¹»ê, Àοø¹èÄ¡, º¸¼ö, ½ÇÀûÆò°¡ ¹æ¹ý, ÀÚ¿ø°ú Ã¥ÀÓ, µµ±¸(Tool) µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2010³â 11¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 91 Pages

»ó±â ÀÚ·á ÀÌ¿ÜÀÇ Cutting Edge Information ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.